

United States Patent and Trademark Office

COPY OF PAPERS ORIGINALLY FILED

www.uspto.gov

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

09/483,504

01/14/2000

Min Teng

5686.200-us

Novo Nordisk of North America Inc 405 Lexington Avenue Suite 6400 New York, NY 10017



CONFIRMATION NO. 8481
FORMALITIES LETTER
OCCO000000008203280

Date Mailed: 05/30/2002

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

Filing Date Granted

Items Required To Avoid Abandonment:

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given **TWO MONTHS** from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The oath or declaration is unsigned.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(i) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.

Items Required To Avoid Processing Delays:

The item(s) indicated below are also required and should be submitted with any reply to this notice to avoid further processing delays.

SUMMARY OF FEES DUE:

Total additional fee(s) required for this application is \$130 for a Large Entity

\$130 Late oath or declaration Surcharge.

: FO::U5_______.30,00 IP


A copy of this notice MUST be returned with the reply.

Customer Service Center





Initial Patent Examination Division (703) 308-1202
PART 2 - COPY TO BE RETURNED WITH RESPONSE



156 COPY OF PAPERS ORIGINALLY FILED

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Teng et al.

Serial No.: 09/483,504

Group Art Unit: To be assigned

Filed: January 14, 2000

Examiner: To be assigned

Confirmation No.: 8481

For: Non-Peptide GLP-1 Agonists

RESPONSE TO NOTICE TO FILE MISSING PARTS

Commissioner for Patents Washington, DC 20231

Sir:

In response to the Notice to File Missing Parts dated May 30, 2002 (a copy thereof is attached hereto), Applicants submit the Executed Combined Declaration and Power of Attorney signed and dated by Applicants for the above-captioned application.

Please charge the required fee, estimated to be \$130.00, with this application and to credit any overpayments to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447. Please credit any overpayment to Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: August 22, 2002

when En Bork Richard W. Bork, Reg. No. 36,459 Novo Nordisk of North America, Inc. 405 Lexington Avenue, Suite 6400 New York, NY 10174-6401

(212) 867-0123

9875800 11/28 5274

23650

PATENT TRADEMARK OFFICE





ttorney Docket No.: 5686.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Teng et al.

Serial No.: 09/483,504

Group Art Unit: To be assigned

Filed: January 14, 2000

Examiner: To be assigned

Confirmation No.: 8481

For: Non-Peptide GLP-1 Agonists

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

- 1. Petition and Fee For Extension of Time (in duplicate)
- 2. Response to Notice to File Missing Parts (in duplicate)
- 3. Copy of Notice to File Missing Parts
- 4. Executed Combined Declaration and Power of Attorney

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents Washington, DC 20231

on August 22, 2002.

Maya Faison-Phillip

(name of person mailing paper)

(signature of person mailing paper)